Peanut Allergy Treatment Market in North America, Europe,
Seattle, June 22, 2022 (GLOBE NEWSWIRE) — According to Coherent Market Insights, the North America, Europe and Australia peanut allergy treatment market is estimated at US DOLLARS$ 1.252.6 million in 2022 and should present a CAGR of 11.7% during the forecast period (2022-2030).
Key trends and analysis of Peanut Allergy Treatment Market in North America, Europe and Australia:
Key market trends include research and development for peanut allergy treatment, which is expected to drive the peanut allergy treatment market growth in North America, Europe, and Australia over the forecast period. For example, on January 26, 2022, Allergy Therapeutics PLC., a pharmaceutical company, announced that the company is expected to initiate the Phase 1 clinical trial for peanut allergy in April 2022, in the United States.
Additionally, the increase in peanut allergy treatment awareness campaigns by market players is expected to propel the peanut allergy treatment market growth in North America, Europe, and Australia over the forecast period. . For example, in August 2021, The Kraft Heinz Company, a food company, announced the “Protection for Peanuts” campaign, a fund for patients to purchase epinephrine injections for the treatment of peanut allergy. peanuts in Canada.
Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/5041
Main market takeaways:
The peanut allergy treatment market in North America, Europe and Australia is expected to grow at a CAGR of 11.7% during the forecast period owing to the increase in research and development for the treatment of peanut allergies by key players, which is expected to drive the North America, Europe and Australia allergy treatment market over the forecast period. For example, in December 2021, DBV Technologies SA, a clinical-stage biopharmaceutical company, announced that the company had initiated a new pivotal Phase 3 clinical study for a modified Viaskin Peanut patch in children of the intended patient population. DBV Technologies SA, also provided an update on Viaskin Peanut’s marketing authorization application to the European Medicines Agency (EMA).
Among drug types, epinephrine segment is estimated to dominate the peanut allergy treatment market in North America, Europe and Australia in 2022 owing to increasing number of drug approvals by regulatory bodies. For example, in November 2017, kaleo, a private pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental new drug application (sNDA) for AUVI-Q (epinephrine injection, USP) 0.1 mg, the first and only epinephrine auto-injector (EAI) specifically designed for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and young children weighing 16.5 to 33 pounds (7.5 to 15 kilograms), who are at risk or have a history of severe allergic reactions.
Based on route of administration, parenteral segment is estimated to dominate the peanut allergy treatment market in North America, Europe and Australia in 2022 owing to increasing number of product launches by major market players. For example, in December 2016, Viatris Inc. (Mylan NV), a healthcare company, announced the launch of the authorized generic product for the EpiPen auto-injector (epinephrine injection, USP). EpiPen is an auto-injector indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis, allergens, idiopathic and exercise-induced anaphylaxis
Key players operating in the peanut allergy treatment market in North America, Europe and Australia are DBV Technologies, Aimmune Therapeutics, Inc., Prota Therapeutics Pty Ltd., COUR Pharmaceuticals, BlueWillow Biologics, HAL Allergy BV, Allergy Therapeutics PLC., Novartis AG. , Regeneron Pharmaceuticals, Inc., Vedanta Biosciences, Inc., Cambridge Allergy Ltd. (Camallergy), Angany Inc., Moonlight Therapeutics Inc., Allero Therapeutics BV, Sanofi, Johnson & Johnson, Viatris Inc. (Mylan NV), Sun Pharmaceutical Industries Ltd., Bayer AG, Aurobindo Pharma Limited., Astellas Pharma Inc., Siolta Therapeutics, DESENTUM OY, ALK, Immunomic Therapeutics, Inc. and Stallergenes Greer Ltd.
Buy now this research report @ https://www.coherentmarketinsights.com/insight/buy-now/5041
Market segmentation :
- Peanut Allergy Treatment Market in North America, Europe and Australia, by Drug Type:
- Drugs in pipeline
- Peanut Viaskin
- Peanut Allergy Treatment Market in North America, Europe and Australia, By Administration:
- Peanut Allergy Treatment Market in North America, Europe and Australia, by Distribution Channel:
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Peanut Allergy Treatment Market in North America, Europe and Australia, by Region:
- North America
- By country
- South West
- South East
- By country
- By country
- Czech and Slovakia
- The rest of Europe
- By country
- North America
Related Market Information Reports:
Chronic Myeloid Leukemia Treatment Marketby drug type (tyrosine kinase inhibitors (imatinib (Gleevec), dasatinib (Sprycel), nilotinib (Tasigna), bosutinib (Bosulif), ponatinib (Iclusig), asciminib (Scemblix) and others), antimetabolites and others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East and Africa) – Size, Share, Prospect Analysis and opportunities, 2022 – 2028
Peanut Allergy Vaccines Market – Analysis of global industry prospects, trends, prospects and opportunities, 2022-2028
Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. Our head office is in India, with a sales office in the world’s financial capital in the USA and sales advisors in the UK and Japan. Our client base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insights in various post-COVID-19 sectors and to continuing to deliver measurable and sustainable results to our clients.
Follow us: LinkedIn | Twitter